Industry Reports Tuesday, Mar 27, 2018

Supernus Pharmaceuticals Inc (SUPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc Key Recent Developments

Mar 14,2018: Supernus Pharmaceuticals May Add Up To 160 New Jobs in Montgomery County

Feb 27,2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance

Nov 06,2017: Supernus Announces Third Quarter 2017 Financial Results

Aug 02,2017: Supernus Announces Record Second Quarter 2017 Financial Results

May 09,2017: Supernus Announces First Quarter 2017 Financial Results